This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is … also characterized by extensive regulation of almost every activity, from product development through manufacturing and … the application of biotechnology to drug development as well as firms that specialize in low-cost production of off-patent …

crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in … the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration … of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the …

The modern law of induced patent infringement contradicts the Patent Act and violates the First Amendment. As currently … using a product in a way that is covered by a patent. This is true even when there is no evidence that prescribers read …-misleading speech for such an attenuated purpose, it also violates the First Amendment. Modern patent inducement law should be revised …

this paper, we take a close look at competition among the generic entrants during the first three years after patent …Pharmaceutical markets experience the entry of numerous generic firms upon expiration of the brand firm's patent. In … expiration and examine whether there is a first mover advantage. We specify a random effect nested logit model of competition …

context of greater or lesser innovation remain important, because competition law enforcement is not suited to playing a … structural role here. Instead, it can help to signal problems, establish principles and guard boundaries. Regulation and … competition are not alternatives, but complementary …

This paper merges patent citation data with data on pharmaceutical patent expirations, generic entry, and pricing to … explore the effects of observable patent characteristics on off-patent and on-patent pharmaceutical pricing. Using a sample of … generic entry. Importantly, I find that the number of patent citations that a drug receives from other firms is correlated …